Diabetes is associated with a poor prognosis in patients with psoriasis and coronary artery disease
Open Access
- 14 July 2025
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-9
Abstract
Background: There is an increased risk of diabetes and cardiovascular disease among patients with psoriasis. However, whether diabetes affects the cardiovascular adverse events in patients with psoriasis who have suffered from coronary artery disease remains unclear. This study aimed to explore the prognostic role of diabetes in this particular population. Methods: This single-center, retrospective cohort study included all consecutive adult patients with psoriasis and coronary artery disease admitted at our hospital between January 2017 and May 2022. Clinical records were collected and compared between patients with and without diabetes. Survival curves were derived using Kaplan–Meier methods. Multivariable Cox regression was used to control potential confounding. Results: This study included 305 participants, including 147 patients (48.2%) with diabetes. Patients with diabetes were more likely to have hypertension (p = 0.045), peripheral vascular disease (p = 0.043) and the history of stroke (p = 0.041). Patients with diabetes also had higher levels of low-density lipoprotein cholesterol (p = 0.039) and homocysteine (p = 0.006). After a median follow-up of 36 months, patients with diabetes had a higher incidence of major adverse cardiovascular events (MACE) than patients without diabetes (p = 0.032). According to the results of the Cox regression analysis, only diabetes (p = 0.039) was associated with MACE. The subgroup analysis showed that diabetes was associated with MACE, especially in male patients (p = 0.008) and those without chronic kidney disease (p = 0.021). Conclusion: In patients with psoriasis and coronary artery disease, diabetes is independently linked with MACE. These findings will help the risk assessment for patients with psoriasis and coronary artery disease.Keywords
Funding Information
- the CAMS Innovation Fund for Medical Sciences (2022-I2M-C&T-A-010)
- the national key Research and Development Program of China (2016YFC1300100)
- the Suzhou Industrial Park Xinxin Cardiovascular Health Foundation "Progress · Progress Fund 2020" funded project (2020-CCA-ACCESS-120)
- the Drug Research Fund for Cardiac Rehabilitation and Metabolic Therapy (T2016-ZX027)
- The National Natural Science Foundation of China (82192902)
This publication has 45 references indexed in Scilit:
- Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational StudyDermatology and Therapy, 2025
- Circadian Oscillations of Minimal Erythema Dose (MED) are Also Influenced by Diet in Patients with Psoriasis: A Chronomedical StudyDermatology and Therapy, 2023
- The Prevalent Comorbidome at the Onset of Psoriasis DiagnosisDermatology and Therapy, 2023
- Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi ConsensusDermatology and Therapy, 2023
- Cysteine and homocysteine as biomarker of various diseasesFood Science & Nutrition, 2020
- Association of Plasma Lipoprotein(a) With Long-Term Adverse Events in Patients With Chronic Kidney Disease Who Underwent Percutaneous Coronary InterventionThe American Journal of Cardiology, 2018
- Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysisInternational Urology and Nephrology, 2018
- Standards of care for type 2 diabetes in ChinaDiabetes/Metabolism Research and Reviews, 2016
- Psoriasis and the Risk of Diabetes MellitusJAMA Dermatology, 2013
- Risk of Myocardial Infarction in Patients With PsoriasisJAMA, 2006